Forward Pharma A/S Banner Image

Forward Pharma A/S

  • Ticker FWP
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Forward Pharma A/S Logo Image
  • 1-10 Employees
  • Based in København K, Denmark
Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the returnMore of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera® or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the Opposition Proceeding, including any appeal thereto.
4.8 / 5.0 (94)

Forward Pharma A/S reports have an aggregate usefulness score of 4.8 based on 94 reviews.

Forward Pharma A/S

Most Recent Annual Report

Forward Pharma A/S
MOST RECENT 2021 Annual Report

Older/Archived Annual Reports

Forward Pharma A/S Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!